Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | Director | May 29, 2026 | June 01, 2026 |
| DBV Technologies S.A.DBVT · Entity 5096 | Director | February 06, 2024 | February 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date May 29, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,908 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Exercise / conversion · Acquired 8,107 · Balance 32,908 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Exercise / conversion · Disposed 8,107 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,311 |
Reported balance
After 2026-05-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-29 · Grant · Acquired 9,311 · Balance 9,311 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.66 · Expires 2036-05-28 | Direct | 16,004 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Grant · Acquired 16,004 · Balance 16,004 F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.
DBV Technologies S.A.
Report date February 06, 2024 · Filed February 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,825 |
Reported balance
After 2024-02-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-02-06 · Purchase · Acquired 1,825 · Balance 1,825 F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"), each of which currently represents one-half of one Ordinary Share. F2: Represent the ADS price. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"), each of which currently represents one-half of one Ordinary Share.
F2: Represent the ADS price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 9,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001865210-26-000002 · form4-06012026_060610.xml · derivative · entry 4 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,311 Underlying: Common Stock · 9,311 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 16,004 | $0.00 Strike: $21.66 | $0.00 |
DisclosureSEC source: 0001865210-26-000002 · form4-06012026_060610.xml · derivative · entry 3 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,004 Underlying: Common Stock · 16,004 shares Expires 2036-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 8,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001865210-26-000002 · form4-06012026_060610.xml · derivative · entry 2 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 8,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001865210-26-000002 · form4-06012026_060610.xml · nonDerivative · entry 1 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 8,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015274 · form4-06022025_060609.xml · derivative · entry 4 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,107 Underlying: Common Stock · 8,107 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 13,793 | $0.00 Strike: $22.29 | $0.00 |
DisclosureSEC source: 0001415889-25-015274 · form4-06022025_060609.xml · derivative · entry 3 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,793 Underlying: Common Stock · 13,793 shares Expires 2035-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015274 · form4-06022025_060609.xml · derivative · entry 2 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,387 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,387 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-015274 · form4-06022025_060609.xml · nonDerivative · entry 1 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| October 12, 2024 Filed Oct 15, 2024 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 4,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-025148 · form4-10152024_061001.xml · derivative · entry 2 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,381 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in two equal annual installments on each of October 12, 2023 and October 12, 2024. F2 · derivative.expiration_date: The restricted stock units vested in two equal annual installments on each of October 12, 2023 and October 12, 2024. Read SEC document |
| October 12, 2024 Filed Oct 15, 2024 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 4,381 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-025148 · form4-10152024_061001.xml · nonDerivative · entry 1 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 9,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015089 · form4-05312024_060517.xml · derivative · entry 4 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,387 Underlying: Common Stock · 9,387 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 15,959 | $0.00 Strike: $14.62 | $0.00 |
DisclosureSEC source: 0001415889-24-015089 · form4-05312024_060517.xml · derivative · entry 3 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,959 Underlying: Common Stock · 15,959 shares Expires 2034-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015089 · form4-05312024_060517.xml · derivative · entry 2 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,652 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-015089 · form4-05312024_060517.xml · nonDerivative · entry 1 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 22:02 UTC | DBV Technologies S.A. DBVT · Entity 5096 | PurchaseOrdinary Shares | 1,825 | $0.89 | $1,624.25 |
DisclosureSEC source: 0001415889-24-003031 · form4-02082024_100252.xml · nonDerivative · entry 1 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,825 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"), each of which currently represents one-half of one Ordinary Share. F2 · price: Represent the ADS price. Read SEC document |
| October 12, 2023 Filed Oct 16, 2023 21:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 4,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-052884 · doc4.xml · derivative · entry 2 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,381 Underlying: Common Stock · 4,381 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in two equal annual installments commencing on the first anniversary of the grant date. F2 · derivative.expiration_date: The restricted stock units shall vest in two equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| October 12, 2023 Filed Oct 16, 2023 21:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 4,381 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052884 · doc4.xml · nonDerivative · entry 1 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:43 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 6,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034698 · doc4.xml · derivative · entry 2 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,652 Underlying: Common Stock · 6,652 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F3 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:43 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 11,045 | $0.00 Strike: $23.90 | $0.00 |
DisclosureSEC source: 0001209191-23-034698 · doc4.xml · derivative · entry 1 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,045 Underlying: Common Stock · 11,045 shares Expires 2033-06-01 F1 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 23:09 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 8,762 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-053710 · doc4.xml · derivative · entry 2 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,762 Underlying: Common Stock · 8,762 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in two equal annual installments commencing on the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units shall vest in two equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 23:09 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (Right to Buy) · Derivative | 14,077 | $0.00 Strike: $17.12 | $0.00 |
DisclosureSEC source: 0001209191-22-053710 · doc4.xml · derivative · entry 1 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,077 Underlying: Common Stock · 14,077 shares Expires 2032-10-11 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in two equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:56 UTC | DBV Technologies S.A. DBVT · Entity 5096 | PurchaseWarrant (right to buy) · Derivative | 6,837 | $7.12 Strike: $13.09 | $48,679.44 |
DisclosureSEC source: 0001209191-21-039889 · doc4.xml · derivative · entry 1 Ndu Adora · CIK 0001865210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,837 Underlying: Ordinary Shares · 6,837 shares Expires 2025-06-10 F1 · derivative.exercise_price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021. F1 · price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.